Fibrobiologics, Inc. (FBLG) Stock Price & Analysis
Fibrobiologics, Inc. (FBLG) fell 7.92% to USD 0.93 as of June 10, 2026 at 07:13 UTC, according to Nexqual real-time market data.
FBLG last closed at USD 1.01; the session ranged USD 0.93–1.01 on volume of 136,112 shares. Market capitalization is $4.84M, with a 52-week range of USD 0.93–19.26 (NCM). Source: Nexqual, June 10, 2026 at 07:13 UTC.
Key Statistics (as of June 10, 2026 at 07:13 UTC)
| Price | USD 0.93 |
|---|---|
| Change | ▼ 7.92% (down) |
| Previous Close | USD 1.01 |
| Open | USD 0.99 |
| Day Range | USD 0.93 – 1.01 |
| 52-Week Range | USD 0.93 – 19.26 |
| Volume | 136,112 shares |
| Market Cap | $4.84M |
| Exchange | NCM |
Technical Analysis (FBLG)
Nexqual's technical model rates FBLG "STRONG SELL" based on 0 bullish and 5 bearish signals across 123 daily candles, as of June 10, 2026 at 07:13 UTC.
| Overall Signal | STRONG SELL |
|---|---|
| RSI (14) | 33.55 (neutral) |
| vs SMA50 | Below (USD 1.34) |
| MACD | -0.16 (negative) |
Analyst Ratings (FBLG)
Wall Street analysts rate FBLG "None" based on 2 analysts, with a mean price target of USD 13.5 (range USD 8–19), per Nexqual as of June 10, 2026 at 07:13 UTC.
| Consensus Rating | None |
|---|---|
| Analyst Count | 2 |
| Mean Target | USD 13.5 |
| High Target | USD 19 |
| Low Target | USD 8 |
| Buy / Hold / Sell | 1 / 1 / 0 |
Earnings (FBLG)
| EPS Estimate | USD -0.93 |
|---|---|
| Revenue Estimate | $0 |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-03-31 | USD -1.33 vs est -1.36 ▲ beat |
| 2025-12-31 | USD -0.6 vs est -2 ▲ beat |
| 2025-09-30 | USD -2.6 vs est -2.3 ▼ miss |
| 2025-06-30 | USD -2.4 vs est -2.4 ▲ beat |
Source: Nexqual, June 10, 2026 at 07:13 UTC.
Financials & Fundamentals (FBLG)
| Gross Margin | +0.00% |
|---|---|
| Operating Margin | +0.00% |
| Profit Margin | +0.00% |
| ROE | -754.75% |
| Debt / Equity | 95.31 |
| Current Ratio | 1.59 |
| Total Cash | $1.48M |
| Total Debt | $2.48M |
| Free Cash Flow | $-8.59M |
Source: Nexqual, June 10, 2026 at 07:13 UTC.
Financial Health Score (FBLG)
Nexqual rates Fibrobiologics, Inc.'s overall financial health "Weak" across five dimensions, as of June 10, 2026 at 07:13 UTC.
| Growth | Mixed — No data |
|---|---|
| Profitability | Weak — Pre-revenue or very early stage |
| Balance Sheet | Mixed — $1M cash vs $2M debt |
| Cash Flow | Weak — Operating cash flow -$15M |
| Efficiency | Critical — ROE -755%, ROA -123.7% |
Ownership (FBLG)
| Insider Ownership | +12.62% |
|---|---|
| Institutional Ownership | +12.52% |
| Shares Outstanding | 5.21M |
| Float | 4.57M |
| Short % of Float | +2.77% |
Source: Nexqual, June 10, 2026 at 07:13 UTC.
Leadership (FBLG)
Fibrobiologics, Inc. is led by Peter O'Heeron (age 61), Founder, Chairperson & CEO, per Nexqual as of June 10, 2026 at 07:13 UTC.
| Founder, Chairperson & CEO | Peter O'Heeron (age 61) |
|---|---|
| Chief Scientific Officer | Hamid Khoja (age 55) |
| Chief Financial Officer | Jason D. Davis (age 53) |
Major Backers & Investors (FBLG)
Notable institutional backers of Fibrobiologics, Inc. include Fund Evaluation Group, LLC, Fidelity, Cascade Financial Partners, LLC , according to Nexqual as of June 10, 2026 at 07:13 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Fund Evaluation Group, LLC | 0.99% |
| Fidelity | 0.49% |
| Cascade Financial Partners, LLC | 0.32% |
| Renaissance Technologies | 0.31% |
| UBS Group AG | 0.11% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| Vanguard Group | 2.73% |
| BlackRock | 0.59% |
| Geode Capital | 0.57% |
Source: Nexqual, June 10, 2026 at 07:13 UTC.
From Fibrobiologics, Inc.'s Latest SEC 10-K Filing (filed 2026-02-24)
Key Strengths & Strategy (as disclosed to the SEC)
- FibroBiologics, Inc., a clinical-stage biotechnology company, engages in the development and commercialization of fibroblast-based therapies for patients suffering from chronic diseases.
- The company's product pipeline includes CYWC628 which has completed pre-clinical trial for the treatment of wound healing; CYMS101 which has completed Phase 1 trial for the treatment of multiple sclerosis; CybroCell for the treatment of degenerative disc disease; and CYPS317 for the treatment of psoriasis.
- It also develops early-stage research products, including CYTER915 to treat the human longevity; and TCB190 for the treatment of certain cancers.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| CLDI | Calidi Biotherapeutics, Inc. | USD 0.18 | ▲ 3.55% |
| GUTS | Fractyl Health, Inc. | USD 0.66 | ▼ 2.21% |
| SXTP | 60 Degrees Pharmaceuticals, Inc | USD 1.39 | ▼ 2.11% |
| TELO | Telomir Pharmaceuticals, Inc. | USD 1.21 | ▲ 0% |
| AZTR | Azitra Inc | USD 0.21 | ▲ 0.62% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 10, 2026 at 07:13 UTC. This page is informational and not investment advice.